1.5T磁共振引导每日自适应SBRT治疗局限期前列腺癌的可行性及初步临床耐受性
本研究前瞻性观察25例局限期前列腺癌患者接受1.5T MR引导每日自适应SBRT(35 Gy/5次/2周)的可行性、生活质量和患者报告结局。结果显示无≥3级不良事件,仅3例(12%)出现2级急性泌尿生殖毒性,患者报告结局无显著恶化,提示该技术安全可行且耐受性良好。
要点
- 35 Gy/5次方案无≥3级毒性,2级泌尿生殖毒性仅12%。
- 每日自适应计划中位时间53分钟,技术可行。
- 患者报告结局问卷未见显著恶化。
核心结论
- 1.5T MR引导每日自适应SBRT治疗局限期前列腺癌初步安全可行,耐受性良好。
研究设计与样本
- 前瞻性观察性研究,纳入25例局限期前列腺癌患者,中位年龄68岁(范围54-82)。
主要发现
- 无≥3级不良事件,3例(12%)出现2级急性泌尿生殖毒性(尿频、尿痛、尿潴留),仅1例轻度直肠疼痛。
- 患者报告结局指标未见相关恶化。
- 中位每次治疗时间53分钟(范围34-86),所有病例均实施每日自适应策略(每日重新勾画关键结构和靶区并重新计划)。
关键数值与推荐
- SBRT方案为35 Gy分5次,2周内完成。
- 毒性评估采用CTCAE v5.0,生活质量评估采用IPSS、ICIQ-SF、IIEF-5、EORTC-QLQ-C30和PR-25问卷。
临床怎么用
- 该方案可作为局限期前列腺癌SBRT的可行选择,需关注急性泌尿生殖毒性。
- 每日自适应流程耗时较长,需合理安排治疗时间。
局限性
- 样本量小(25例),随访时间短,仅为初步报告。
- 需要更成熟的数据进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Unity Elekta is a unique magnetic resonance (MR)-linac that conjugates a 1.5 Tesla MR unit with a 7 MV flattening filter free accelerator.A prospective observational study for the clinical use of Elekta Unity is currently ongoing in our department. Herein, we present our preliminary report on the feasibility, quality of life, and patient-reported outcomes measures (PROMs) for localized prostate cancer (PC) treated with stereotactic body radiotherapy (SBRT). METHODS: The SBRT protocol consisted of a 35 Gy schedule delivered in 5 fractions within 2 weeks. Toxicity and quality of life (QoL) were assessed at baseline and after treatment using the Common Terminology Criteria for Adverse Events v5.0, International Prostatic Symptoms Score (IPSS), ICIQ-SF, IIEF-5, and EORTC-QLQ-C30 and PR-25 questionnaires. RESULTS: Between October 2019 and January 2020, 25 patients with localized PC were recruited. The median age was 68 years (range, 54-82); 4 were low risk, 11 favorable intermediate risk (IR) and 10 unfavorable IR. Median iPSA was 6.8 ng/ml (range, 1-19), and 9 of these patients (36%) received concurrent androgen deprivation therapy. Median prostate volume was 36 cc (range, 20-61); median baseline IPSS was 5 (range, 0-10). Median time for fraction was 53 min (range, 34-86); adaptive strategy with daily critical structure and target re-contouring and daily replanning (adapt to shape) was performed in all cases. No grade ≥ 3 adverse event was observed, three patients (12%) reported grade 2 acute genitourinary toxicity (urinary frequency, urinary tract pain and urinary retention), while only one patient reported mild rectal pain. No relevant deteriorations were reported in PROMs. CONCLUSION: To the best of our knowledge, this is the first experience reporting feasibility, clinician-reported outcome measurements, and PROMs for 1.5 T MR-guided adaptive SBRT for localized prostate cancer. The preliminary data collected here report optimal safety and excellent tolerability, as also confirmed by PROMs questionnaires. Moreover, the data on technical feasibility and timing of online daily adapted planning and delivery are promising. More mature data are warranted. TRIAL REGISTRATION: Date of approval April 2019 and numbered MRI/LINAC n°23,748.
引用
- Alongi F, Rigo M, Figlia V, et al. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. Radiat Oncol. 2020. PMID: 32248826. doi:10.1186/s13014-020-01510-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。